Ototoxicity, or permanent and irreversible hearing loss, occurs in up to 50-60% of adult and 90% of paediatric patients. Credit: Anthony Camerlo on Unsplash.

Sensorion has reported the enrolment of the first patient in its Phase IIa proof of concept clinical trial of SENS-401 (Arazasetron) in cisplatin-induced ototoxicity patients.

The exploratory, randomised, multicentre, controlled, open-label NOTOXIS clinical trial will assess SENS-401’s efficacy for the prevention of ototoxicity induced by the cisplatin compound in adult neoplastic disease patients.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Eligible trial participants will be randomised on day one into either Arm A or Arm B on a 1:1 basis.

A maximum of 58 participants in total are expected to be enrolled, with 29 participants in each arm.

Participants in Arm A will receive treatment with cisplatin-based chemotherapy without receiving SENS-401.

Arm B subjects will be given 43.5mg of oral SENS-401 one week before starting the cisplatin treatment, during the complete duration of the chemotherapy treatment, and four weeks after receiving the last cisplatin cycle.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial’s primary objective will be the evaluation of SENS-401 efficacy measuring the change from baseline of the average Pure Tone Audiometry (PTA) four weeks after concluding cisplatin treatment.

In addition, the trial will evaluate several secondary outcome measures including the change in PTA (dB) throughout the study, tolerance, and the rate and severity of ototoxicity.

Sensorion chief medical officer Géraldine Honnet said: “While Cisplatin is a highly effective treatment for many cancers, it is associated with hearing loss in so many adult and paediatric patients.

“The preclinical and clinical data gathered during SENS-401 development support Sensorion’s confidence in its potential to preserve hearing for patients receiving cisplatin, without impacting chemotherapeutic potential, and we are therefore very excited to be commencing this trial.”

Interim data from the trial is expected in the first half of this year.

Ototoxicity, or permanent and irreversible hearing loss, occurs in up to 50-60% of adult and 90% of paediatric patients who survive cancer.

In January last year, Sensorion’s Phase II AUDIBLE-S clinical trial of SENS-401 to treat sudden sensorineural hearing loss failed to meet the primary goal.